首页> 外文OA文献 >Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty

【2h】

Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty

机译：口服血小板糖蛋白IIb / IIIa受体拮抗剂来氟地班的药效学和安全性在稳定的冠状动脉疾病接受选择性血管成形术的患者中

页面导航

著录项
相似文献
相关主题

著录项

作者
Akkerhuis K.M. (Martijn); Simoons M.L. (Maarten); Zwaan C. (Coen) van der; Suryapranata H. (Harry); Stibbe J. (Jeanne); Hoffmann J.; Baardman T. (Taco); Brand M.J.B.M. (Marcel) van den; Deckers J.W. (Jaap); Wieken L.R. (Ron) van der; Peels H.O.J.;
展开▼
作者单位

展开▼
年度 2001
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein Iib/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty [J] . K M Akkerhuis, M J B M van den Brand, C van der Zwaan Heart . 2001 ,第4期

机译：口服血小板糖蛋白Iib / IIIa受体拮抗剂来氟地班的药效学和安全性在稳定的冠状动脉疾病接受择期血管成形术的患者中
2. Pharmacokinetics and Pharmacodynamics of Argatroban in Combination With a Platelet Glycoprotein IIB/IIIA Receptor Antagonist in Patients Undergoing Percutaneous Coronary Intervention. [J] . Cox DS, Kleiman NS, Boyle DA, The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2004 ,第9期

机译：Argatroban与血小板糖蛋白IIB / IIIA受体拮抗剂联合在接受经皮冠状动脉介入治疗的患者中的药代动力学和药效学。
3. Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integr [J] . Breeman A, Mercado N, Lenzen M, Cardiology . 2002 ,第4期

机译：非ST段抬高的急性冠状动脉综合征和多支冠状动脉疾病患者的特征，治疗和预后：来自PURSUIT的观察（不稳定型心绞痛的血小板糖蛋白IIb / IIIa：使用整数抑制受体
4. The Long-Term Clinical Results of a Platelet Glycoprotein Ilb/IIIa Receptor Blocker (Abciximab: ReoPro~R)-Coated Stent in Patients with Coronary Artery Disease [C] . W. Kim, M.H. Jeong, Y.J. Hong, International Congress on Thrombosis . 2004

机译：冠状动脉疾病患者的血小板糖蛋白ILB / IIIA受体阻滞剂（Abciximab：Reopro〜R）涂层支架的长期临床结果
5. A comparison of selected preoperative coronary artery disease risk factors in patients 40 years or younger and patients over 40 years undergoing coronary artery bypass graft surgery. [D] . Frye, Laurie Perry. 2002

机译：比较40岁以下的患者和40岁以上进行冠状动脉搭桥术的患者的术前选择的冠心病危险因素。
6. Pharmacodynamics and safety of lefradafiban an oral platelet glycoprotein IIb/IIIa receptor antagonist in patients with stable coronary artery disease undergoing elective angioplasty [O] . K Akkerhuis, M J B M van den Brand, C van der Zwaan, 2001

机译：口服血小板糖蛋白IIb / IIIa受体拮抗剂来氟地班的药效学和安全性在稳定的冠状动脉疾病接受选择性血管成形术的患者中
7. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty [O] . Akkerhuis, K, van den Brand, M J B M, van der Zwaan, C, 2001

机译：口服血小板糖蛋白IIb / IIIa受体拮抗剂来氟地班的药效学和安全性在稳定的冠状动脉疾病接受选择性血管成形术的患者中

Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty

著录项

相似文献

相关主题

期刊订阅